Citius Oncology, Inc. (CTOR) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $7.32M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $7.32M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $7.32M |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 71.71M USD | Liabilities |
| Borrowing debt | (m) | |
| Amounts owed to suppliers | 7.32M USD | Accounts Payable, Current |
| Total deferred revenue | (m) | |
| Deferred revenue due within one year | (m) | |
| Deferred revenue due after one year | (m) | |
| Reported other obligations due within one year | (m) | Other Liabilities, Current |
| Reported other noncurrent obligations | (m) | |
| Deferred revenue included in other noncurrent obligations | (m) |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Obligation categories | (m) |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $7.32M | (m) | (m) | (m) | $71.71M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $8.88M | (m) | (m) | (m) | $65.43M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $10.45M | (m) | (m) | (m) | $51.56M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $13.23M | (m) | (m) | (m) | $56.08M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $8.67M | (m) | (m) | (m) | $59.31M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $7.68M | (m) | (m) | (m) | $55.80M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $5.87M | (m) | (m) | (m) | $49.19M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $3.71M | (m) | (m) | (m) | $38.23M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $1.29M | (m) | (m) | (m) | $22.20M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | $349.98K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |